(Q36266356)

13 August 2017

1 reference

title

Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review (English)

1 reference

13 August 2017

1 reference

5

Kumanan Wilson

1 reference

13 August 2017

Dean Fergusson

1

1 reference

13 August 2017

Brian Hutton

2

1 reference

13 August 2017

Michael Sharma

3

1 reference

13 August 2017

Alan Tinmouth

4

1 reference

13 August 2017

D William Cameron

6

1 reference

13 August 2017

Paul C Hebert

7

1 reference

13 August 2017

publication date

1 October 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

45

1 reference

13 August 2017

issue

10

1 reference

13 August 2017

page(s)

1640-1657

1 reference

Treatment of Guillain-Barré syndrome: a cost-effectiveness analysis

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Safety and efficacy of intravenous immunoglobulin prophylaxis in pediatric head trauma patients: a double-blind controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

An expert system for the evaluation of EDSS in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

The psychometric properties of clinical rating scales used in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1537-2995.2005.00581.X

10.1111/J.1537-2995.2005.00581.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference